On December 5, 2025, Stoke Therapeutics, Inc. (STOK) disclosed an insider transaction in a Form 4 filing with the U.S. Securities and Exchange Commission (SEC). The filing revealed that Chief Executive Officer Edward M. Kaye sold 10,000 shares of the company's common stock.

According to the filing, the transaction was executed on December 3, 2025, at a price of $15.00 per share, resulting in a total transaction value of $150,000. The sale was conducted pursuant to a Rule 10b5-1 trading plan that CEO Edward M. Kaye adopted on August 15, 2025.

Rule 10b5-1 plans allow company insiders to establish pre-arranged trading plans for selling shares they own. These plans are designed to prevent accusations of insider trading by setting trading parameters in advance, according to SEC regulations.